Why this matters now

Seasonal and indoor allergies affect a large share of the U.S. population and are worsening with longer pollen seasons. National surveillance estimates show roughly one‑third of U.S. adults report an allergy, and more than a quarter report seasonal allergies; pollen exposure contributes billions in annual medical costs and exacerbates asthma. Climate change is lengthening pollen seasons and increasing pollen concentrations, intensifying disease burden. [1][2][3]

What “evidence‑based SLIT with physician oversight” means here> What the guidelines say (quick refs)

• AAO‑HNS recognizes sublingual immunotherapy (SLIT) as an effective, guideline‑supported option for allergic rhinitis when used with FDA‑approved tablets or clinically dosed extracts under physician oversight (Wyndly SLIT protocols → AAO‑HNS).
• Cochrane Reviews (2003, 2010) concluded SLIT is effective and safe for environmental allergies (summary and citations; overview).
• Allergies are common: 31.8% of U.S. adults report any allergy; 25.7% report seasonal allergies (CDC FastStats); AAAAI/ACAAI outline high national burden and immunotherapy’s role (ACAAI Facts & Stats; AAAAI stats).
• Climate change is lengthening pollen seasons and raising pollen loads, increasing disease burden (CDC – Allergens & Pollen).
• Telehealth delivery in Allergy/Immunology shows very high patient satisfaction and safe care when protocols are followed (JACI In Practice review). Sublingual immunotherapy (SLIT) uses precisely dosed allergen extracts placed under the tongue to build immune tolerance over time. Under physician direction, SLIT can be delivered as FDA‑approved tablets for specific allergens (e.g., grasses, ragweed, dust mites) or as clinically dosed multi‑allergen drops when appropriate. The goal is durable symptom reduction by addressing the immune cause rather than repeatedly masking symptoms.

At Wyndly, board‑certified physicians:

• Confirm triggers with CLIA‑certified IgE testing and clinical history.

• Select FDA‑approved SLIT tablets when available and apply clinically validated dosing protocols for oral drops when needed.

• Screen for contraindications and monitor progress with regular check‑ins and on‑demand access.

• Coordinate care fully via telehealth to expand access while maintaining medical standards. See our full evidence and protocols in the Wyndly SLIT evidence dossier.

What the independent evidence shows (plain English)

• Allergies are common and costly: ~31.8% of U.S. adults report any allergy; seasonal allergies affect tens of millions and drive significant healthcare use. [1][3]

• Pollen exposure is rising: higher CO₂ and warmer seasons lengthen pollen seasons and raise pollen loads, increasing symptoms and risk of asthma attacks. [2]

• Immunotherapy works by retraining immunity: gradually increasing allergen doses shift immune response and reduce symptoms over a multi‑year course (typically three to five years for shots; sublingual products follow the same immunologic principle). [4]

• SLIT is established and increasingly accessible: the U.S. has FDA‑approved sublingual tablets (e.g., for grasses, ragweed, dust mite). Virtual clinics are expanding access for patients who cannot attend frequent shot visits. [5]

• Telehealth delivery is viable and well‑accepted: allergy practices successfully use synchronous and asynchronous telemedicine with high patient satisfaction and safe remote monitoring; hybrid models help address the national allergist shortage. [6]

How our physician‑led model applies the evidence

• Diagnosis first: IgE blood testing plus clinical history to target the right allergens and avoid unnecessary therapies.

• Right therapy for the right allergen: FDA‑approved tablets when indicated; multi‑allergen drops using established oral dosing protocols when tablets are unavailable or when patients have multiple clinically relevant allergens. Ongoing dose adjustments are physician‑directed.

• Safety and suitability: doctors screen for contraindications (e.g., EoE, certain medication overlaps, pregnancy) and counsel on expected timelines (most patients notice improvement within weeks to months; durable tolerance requires sustained therapy).

• Outcomes tracking: symptom scores, medication use, and patient‑reported function guide adjustments during follow‑up.

Reference snapshot

Explore the full evidence

For dosing frameworks, safety data, tablet indications, and links to peer‑reviewed studies used in our protocols, see: Wyndly SLIT evidence dossier.

References

1) American College of Allergy, Asthma & Immunology (ACAAI) – Facts & Stats: https://acaai.org/allergies/allergies-101/facts-stats/

2) U.S. CDC – Allergens & Pollen and Climate Effects: https://www.cdc.gov/climate-health/php/effects/allergens-and-pollen.html

3) U.S. CDC – FastStats: Allergies: https://www.cdc.gov/nchs/fastats/allergies.htm

4) Harvard Health Publishing – Allergy shots (Allergen immunotherapy) A‑to‑Z: https://www.health.harvard.edu/diseases-and-conditions/allergy-shots-allergen-immunotherapy-a-to-z

5) Undark – Virtual clinics embrace allergy drops and FDA‑approved tablets: https://undark.org/2023/08/09/virtual-allergy-clinics-embrace-drops-over-shots/

6) JACI In Practice – Telehealth in Allergy/Immunology (review): https://pmc.ncbi.nlm.nih.gov/articles/PMC9420069/